On March 2, 2021 Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, reported their collaboration with Immunitas Therapeutics, Inc. (www.immunitastx.com) for the development of a systems pharmacology model for an oncology pathway with complex receptor-ligand dynamics (Press release, Applied BioMath, MAR 2, 2021, View Source [SID1234575975]). The model will be used to understand the importance of targeting multiple receptors simultaneously and will inform the optimal therapeutic modality. "Efficiently translating early research into a clinical candidate is a top priority at Immunitas," said Tarek Samad, CSO of Immunitas. "We look forward to leveraging Applied BioMath’s mathematical models to better understand the best path forward for this therapeutic program."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Applied BioMath employs a rigorous fit-for-purpose model development process which quantitatively integrates knowledge about therapeutics with an understanding of its mechanism of action in the context of human disease mechanisms. Their approach employs proprietary algorithms and software that were designed specifically for systems pharmacology model development, simulation, and analysis. "Our proprietary software platforms and high-performance computing were designed to model biological systems and enable us to compare various dosing regimens more quickly than traditional approaches," said John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath. "This ability early on in therapeutic R&D is critical and we are excited to collaborate with Immunitas on this project."

On March 2, 2021 Pfizer reported its Ibrance has held a strong lead in market share—and sales—over Eli Lilly’s Verzenio (Press release, Eli Lilly, MAR 2, 2021, View Source [SID1234576169]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

But on the heels of Verzenio’s strong showing in HR+/HER2- early breast cancer—and Ibrance’s miss—one influential analyst figures the Lilly drug will quickly pick up steam. The upshot? About $4.6 billion in sales at the peak, significantly more than most pharma watchers now expect from the med.

Since its launch in 2017, Verzenio’s share of the market in metastatic breast cancer has been "steadily growing," from 12% early last year to 20% now, Bernstein analyst Ronny Gal wrote in a Monday note to clients. And with a potential launch in HR+/HER2- early breast cancer, the drug’s sales are set to ramp up considerably, he said.

WEBINAR
Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes
Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.
REGISTER NOW
Lilly is "showing success with arguing for differentiation from Ibrance, and the growth will continue when the drug gains approval" in early breast cancer, the analyst wrote. The prediction comes after Verzenio posted impressive data in HR+/HER2- early breast cancer—and after Ibrance failed two studies in early breast cancer.

RELATED: Lilly’s Verzenio pressures Pfizer with practice-changing win in early breast cancer

Pfizer’s drug won an FDA approval in 2015 and generated $5.4 billion in sales last year. Verzenio, for its part, scored an FDA approval in 2017—giving Pfizer a considerable head start—and brought in $913 million last year.

While Pfizer’s drug is already on a strong sales trajectory, Gal says Lilly can expect Verzenio to not only pass the $1 billion blockbuster threshold but gin up billions more than that each year.

Ibrance will "retain market leadership" in metastatic breast cancer, Gal wrote, but he sees Verzenio snagging 28% of that market by 2024. With those share gains plus a potential FDA nod in early breast cancer, Bernstein analysts project $4.6 billion in Verzenio sales in 2024, significantly higher than consensus Wall Street estimates of $3.2 billion.

RELATED: Pfizer’s Ibrance kisses early breast cancer hopes goodbye with 2nd study failure

Last summer, Lilly’s drug—added to standard endocrine therapy after surgery—showed it could significantly reduce the risk of cancer recurrence by 25.3% in patients with high-risk HR-positive, HER2-negative early breast cancer.

One expert said the findings would "change practice." The company filed the data with regulators in the fourth quarter of 2020, according to its recent annual SEC filing.

Meanwhile, Pfizer’s Ibrance has failed two studies in early breast cancer. After the second failure, SVB Leerink analyst Geoffrey Porges wrote that there’s "no saving adjuvant for Ibrance."

On March 2, 2021 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported that James Dentzer, President and Chief Executive Officer of Curis, will present a company overview at the H.C. Wainwright & Co. Global Life Sciences Conference (Press release, Curis, MAR 2, 2021, View Source [SID1234575912]). A pre-recorded presentation will be available for on-demand viewing beginning at 7:00 am ET on Tuesday, March 9, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company’s website at www.curis.com. A replay of the webcast will be available on the Curis website for approximately 90 days following the event.

On March 2, 2021 Genmab A/S (Nasdaq: GMAB) reported that it will increase its share capital by 41,574 shares as a consequence of the exercise of employee warrants (Press release, Genmab, MAR 2, 2021, View Source [SID1234575928]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

600 shares at DKK 31.75,
21,690 shares at DKK 40.41,
125 shares at DKK 55.85,
300 shares at DKK 220.40,
1,000 shares at DKK 225.30,
73 shares at DKK 815.50,
3,563 shares at DKK 939.50,
10,005 shares at DKK 1,032.00,
250 shares at DKK 1,136.00,
3,176 shares at DKK 1,145.00,
300 shares at DKK 1,233.00,
367 shares at DKK 1,408.00,
85 shares at DKK 1,424.00, and
40 shares at DKK 1,432.00.

Proceeds to the company are approximately DKK 19.9 million. The increase corresponds to approximately 0.06% of the company’s share capital.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2020. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.

Pursuant to section 32 of the Danish Capital Markets Act No. 1767 of November 27, 2020, it is hereby announced, that the total nominal value of Genmab A/S’ share capital after the capital increase is DKK 65,587,322 which is made up of 65,587,322 shares of a nominal value of DKK 1 each, corresponding to 65,587,322 votes.

On March 2, 2021 Bio-Techne Corporation (NASDAQ: TECH) reported that Chuck Kummeth, President and Chief Executive Officer, will present at the Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 9:10 a.m. EST (Press release, Bio-Techne, MAR 2, 2021, View Source [SID1234575944]). A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne’s Investor Relations website at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!